Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.R&D costs drive down Bristol-Myers earnings
Bristol-Myers Squibb posted Q2 2006 net sales from continuing operations of $4.9 billion and net earnings from continuing operations of $667 million, or $0.34 per diluted share, compared
Bristol-Myers Squibb posted Q2 2006 net sales from continuing operations of $4.9 billion and net earnings from continuing operations of $667 million, or $0.34 per diluted share, compared
The data safety monitoring board (DSMB) reviewed the second planned interim analysis of data for efficacy in Genitope’s pivotal phase III clinical trial in follicular non-Hodgkin’s lymphoma (fNHL)
The therapeutic protein being licensed by Nostrum is known as clot-specific streptokinase (CSSK), which was developed at The Institute of Microbial Technology (IMTECH), an institute governed by the
In US National Institutes of Health-funded study, scientists found that Nexrutine, a proprietary extract from the bark of the Phellodendron tree, prevented the growth of prostate cancer cells.
Most hypertensive patients, especially those with other associated risk factors, now require multiple therapies using more than one drug to keep their blood pressure at desired levels. Fixed
Initial indications of this collaborative research agreement will focus on how to use knowledge of T-cell signaling pathways to design novel cancer therapeutics and broaden to other indications
The clinical trial included 21 neonatal intensive care units throughout the US, enrolling infants with birth weights between 500g and 1,250g. Their median gestational age was 26 weeks.
Total revenues increased by 3.3%, or 3.9% in local currencies, to $699.2 million in the second quarter of 2006, compared to $676.8 million in Q2 2005. Product sales
The agreement covers the sale of reporter assay kits that use a novel secreted luciferase isolated by Bayer scientists from the marine copepod, Metridia longa. Under the terms
Cambridge Antibody Technology (CAT) obtains access to Molecular Partners’ proprietary designed repeat proteins (DRPs) technology and Molecular Partners gains rights to intellectual property in ribosome display, controlled by